Estimating the contribution of HIV-infected adults to household pneumococcal transmission in South Africa, 2016-2018: A hidden Markov modelling study.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
12 2021
Historique:
received: 20 05 2021
accepted: 24 11 2021
entrez: 23 12 2021
pubmed: 24 12 2021
medline: 12 2 2022
Statut: epublish

Résumé

Human immunodeficiency virus (HIV) infected adults are at a higher risk of pneumococcal colonisation and disease, even while receiving antiretroviral therapy (ART). To help evaluate potential indirect effects of vaccination of HIV-infected adults, we assessed whether HIV-infected adults disproportionately contribute to household transmission of pneumococci. We constructed a hidden Markov model to capture the dynamics of pneumococcal carriage acquisition and clearance observed during a longitudinal household-based nasopharyngeal swabbing study, while accounting for sample misclassifications. Households were followed-up twice weekly for approximately 10 months each year during a three-year study period for nasopharyngeal carriage detection via real-time PCR. We estimated the effect of participant's age, HIV status, presence of a HIV-infected adult within the household and other covariates on pneumococcal acquisition and clearance probabilities. Of 1,684 individuals enrolled, 279 (16.6%) were younger children (<5 years-old) of whom 4 (1.5%) were HIV-infected and 726 (43.1%) were adults (≥18 years-old) of whom 214 (30.4%) were HIV-infected, most (173, 81.2%) with high CD4+ count. The observed range of pneumococcal carriage prevalence across visits was substantially higher in younger children (56.9-80.5%) than older children (5-17 years-old) (31.7-50.0%) or adults (11.5-23.5%). We estimate that 14.4% (95% Confidence Interval [CI]: 13.7-15.0) of pneumococcal-negative swabs were false negatives. Daily carriage acquisition probabilities among HIV-uninfected younger children were similar in households with and without HIV-infected adults (hazard ratio: 0.95, 95%CI: 0.91-1.01). Longer average carriage duration (11.4 days, 95%CI: 10.2-12.8 vs 6.0 days, 95%CI: 5.6-6.3) and higher median carriage density (622 genome equivalents per millilitre, 95%CI: 507-714 vs 389, 95%CI: 311.1-435.5) were estimated in HIV-infected vs HIV-uninfected adults. The use of ART and antibiotics substantially reduced carriage duration in all age groups, and acquisition rates increased with household size. Although South African HIV-infected adults on ART have longer carriage duration and density than their HIV-uninfected counterparts, they show similar patterns of pneumococcal acquisition and onward transmission.

Identifiants

pubmed: 34941865
doi: 10.1371/journal.pcbi.1009680
pii: PCOMPBIOL-D-21-00940
pmc: PMC8699682
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009680

Subventions

Organisme : Wellcome Trust
ID : 208812/Z/17/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2011;6(11):e27929
pubmed: 22140487
AIDS. 2001 May 25;15(8):957-64
pubmed: 11399977
PLoS One. 2013 Nov 04;8(11):e78592
pubmed: 24223825
Lancet Glob Health. 2021 Jun;9(6):e863-e874
pubmed: 34019838
Lancet. 2009 Sep 12;374(9693):893-902
pubmed: 19748398
PLoS Pathog. 2017 Dec 21;13(12):e1006665
pubmed: 29267378
Am J Epidemiol. 2013 Dec 1;178(11):1629-37
pubmed: 24091888
Ecol Lett. 2020 Dec;23(12):1878-1903
pubmed: 33073921
Lancet. 2019 May 25;393(10186):2146-2154
pubmed: 31000194
PLoS Comput Biol. 2019 Dec 26;15(12):e1007589
pubmed: 31877122
AIDS. 2015 Sep 10;29(14):1837-44
pubmed: 26218599
Bull World Health Organ. 2016 Oct 1;94(10):772-776
pubmed: 27843168
J Infect Dis. 2008 Apr 1;197(7):1000-5
pubmed: 18419536
Nature. 2019 Jun;570(7760):189-193
pubmed: 31092927
J Clin Microbiol. 2007 Oct;45(10):3408-10
pubmed: 17699645
BMC Med. 2020 Jun 10;18(1):129
pubmed: 32517683
PLoS One. 2012;7(5):e38271
pubmed: 22693610
Hum Vaccin Immunother. 2012 Feb;8(2):161-73
pubmed: 22426374
BMC Public Health. 2016 Sep 06;16:938
pubmed: 27600800
PLoS One. 2011 Mar 15;6(3):e17765
pubmed: 21423577
Am J Epidemiol. 2019 Jan 1;188(1):160-168
pubmed: 30462150
Expert Rev Vaccines. 2020 Nov;19(11):1085-1092
pubmed: 33269987
Vaccine. 2018 Nov 19;36(48):7369-7376
pubmed: 30352744
BMC Med. 2019 Dec 5;17(1):219
pubmed: 31801542
Epidemiol Infect. 2017 Oct;145(13):2750-2758
pubmed: 28847317
Elife. 2017 Jul 25;6:
pubmed: 28742023
Travel Med Infect Dis. 2018 Jul - Aug;24:89-100
pubmed: 29860151
Lancet Glob Health. 2018 Jul;6(7):e744-e757
pubmed: 29903376
Am J Epidemiol. 2007 Jul 15;166(2):228-35
pubmed: 17517684
Epidemiol Infect. 2005 Oct;133(5):891-8
pubmed: 16181510
Vaccine. 2015 Aug 26;33(36):4430-6
pubmed: 26141012
Pediatr Infect Dis J. 2018 Oct;37(10):1054-1060
pubmed: 30216295
Epidemiol Infect. 2017 Aug;145(11):2390-2399
pubmed: 28712384
Stat Med. 2002 Jan 15;21(1):113-28
pubmed: 11782054
Drugs. 2008;68(11):1473-81
pubmed: 18627205
Am J Epidemiol. 2016 Jan 1;183(1):70-8
pubmed: 26628514
J Infect Dis. 2005 Jun 15;191(12):2038-45
pubmed: 15897989
Influenza Other Respir Viruses. 2021 Nov;15(6):789-803
pubmed: 34296810
Pediatr Infect Dis J. 2013 May;32(5):e192-205
pubmed: 23340555
Clin Infect Dis. 2021 Jun 1;72(11):e768-e775
pubmed: 32989457
Med Decis Making. 2017 Oct;37(7):779-789
pubmed: 28379779
Nat Commun. 2020 May 6;11(1):2222
pubmed: 32376860
Epidemiology. 2012 Jul;23(4):510-9
pubmed: 22441543
Epidemiol Infect. 2004 Jun;132(3):433-41
pubmed: 15188713
Biostatistics. 2004 Apr;5(2):223-37
pubmed: 15054027
Pediatr Infect Dis J. 2005 May;24(5):410-6
pubmed: 15876939
Clin Infect Dis. 2019 Apr 24;68(9):1512-1521
pubmed: 30165376
Clin Infect Dis. 2011 May;52 Suppl 4:S331-7
pubmed: 21460292
Lancet. 2019 May 25;393(10186):2102-2104
pubmed: 31000193
Stat Med. 2003 Feb 15;22(3):441-62
pubmed: 12529874

Auteurs

Deus Thindwa (D)

Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.

Nicole Wolter (N)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.

Amy Pinsent (A)

Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Aquarius Population Health, London, United Kingdom.

Maimuna Carrim (M)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.

John Ojal (J)

Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
KEMRI-Wellcome Trust Research Programme, Geographic Medicine Centre, Kilifi, Kenya.

Stefano Tempia (S)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa.
Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
MassGenics, Duluth, Georgia, United States of America.

Jocelyn Moyes (J)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.

Meredith McMorrow (M)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

Jackie Kleynhans (J)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
School of Public Health, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.

Anne von Gottberg (AV)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.

Neil French (N)

Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
Institute of Infection, Veterinary and Ecological Science, Department of Clinical Infection, Microbiology, and Immunology, University of Liverpool, Liverpool, United Kingdom.

Cheryl Cohen (C)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
School of Public Health, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.

Stefan Flasche (S)

Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH